Clinical reference Biomarker Directory
Back to directory

Anti-Streptolysin antibodies

Established

ASO is an antibody marker of recent strep infection, supporting (not confirming) rheumatic fever diagnosis.

Also known as ASO antistreptolysin O titer
In plain language

ASO shows the body has recently fought off a strep infection. It's a clue, not a stand-alone diagnosis, for rheumatic fever or a related kidney inflammation, and doctors combine it with other findings and antibody tests to be sure.

Biomarker & context

Antistreptolysin O (ASO) antibodies form in response to streptolysin O, a toxin produced by group A Streptococcus. ASO titers reflect a recent (not current) streptococcal infection.

What it indicates

Elevated ASO supports evidence of preceding strep infection in patients being evaluated for rheumatic fever or post-streptococcal glomerulonephritis, per the modified Jones criteria, but does not itself diagnose either condition.

Diagnosis & clinical testing

Measured via serum titer; levels rise 1–5 weeks after infection and can remain elevated for weeks to months. Roughly 15–20% of confirmed rheumatic fever patients never show an ASO rise, so anti-DNase B testing is often added to reduce false negatives.

Guiding treatment

ASO alone should not guide antibiotic or long-term prophylaxis decisions for rheumatic fever; it is one input alongside the full Jones criteria clinical picture.

Clinical significance

Supportive evidence within the Jones criteria; roughly 15-20% of true rheumatic fever cases show no ASO rise.

References
  1. AAFP. (2005). Evaluation of Poststreptococcal Illness.
  2. Testing.com. (2020). Antistreptolysin O (ASO) Test: Purpose and Results.